Deep brain stimulation is an effective treatment for obsessive–compulsive disorder but is rarely used. Action is needed by psychologists, psychiatrists and insurers so that patients with otherwise intractable cases can receive this therapy to improve their mental health.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hirschtritt, M. E. et al. J. Am. Med. Assoc. 317, 1358–1367 (2017).
Moro, E. & Cury, R. G. Moving Along 25, 6–7 (2021).
Pepper, J. et al. J. Neurosurg. 11, 1–10 (2019).
Nuttin, B. et al. Lancet 354, 1526 (1999).
Park, Y. S. et al. World. Neurosurg 126, 1–10 (2019).
US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375533 (15 April 2022).
Davis, R. A. et al. Front. Psychiatry 12, 706181 (2021).
Nuttin, B. et al. J. Neurol. Neurosurg. Psychiatry 85, 1003–1008 (2014).
Denys, D. et al. Arch. Gen. Psychiatry 67, 1061–1068 (2010).
Luyten, L. et al. Mol. Psychiatry 21, 1272–1280 (2016).
Mosley, P. E. et al. Transl. Psychiatry 11, 190 (2021).
Provenza, N. R. et al. Nat. Med. 27, 2154–2164 (2021).
Winter, L. et al. Neuromodulation 24, 324–330 (2021).
Graat, I. et al. Biol. Psychiatry 90, 714–720 (2021).
Mallet, L. et al. N. Engl. J. Med. 359, 2121–2134 (2008).
Tyagi, H. et al. Biol. Psychiatry 85, 726–734 (2019).
Welter, M. L. et al. Biol. Psychiatry 90, e45–e47 (2020).
Kohl, S. et al. Neuromodulation 19, 542–544 (2016).
Pellegrini, L. et al. Compr. Psychiatry 108, 152246 (2021).
Pinckard-Dover, H. et al. Front. Surg. 8, 642503 (2021).
Naesström, M. et al. Surg. Neurol. Int. 8, 298 (2017).
Cormier, J. et al. Can. J. Neurol. Sci. 46, 303–310 (2019).
P.K. reports research or educational grants from the Swiss National Science Foundation (FNS 323530_177577, FNS 2020 32003BL_197709-1 and FNS 33IC30_198772), paid to his employing institution. M.S.O. has received research grants from the US National Institutes of Health (R01 NR014852, R01NS096008, UH3NS119844 and U01NS119562; training grant R25NS108939 (Principal Investigator)).
V.V.-V. is a member of advisory boards and has received speaker’s honoraria from Medtronic, Boston Scientific and Abbott. P.K. reports research or educational grants from Roger de Spoelberch Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Michael J. Fox Foundation, Aleva Neurotherapeutics, Boston Scientific, Medtronic, GE Healthcare and Idorsia, paid to his employing institution; lecturing fees from Boston Scientific and Bial, paid to his employing institution; travel expenses to scientific meetings from Boston Scientific, Zambon and Abbvie. L.Z. has received honoraria for educational activities from Elekta, Boston Scientific and Medtronic. A.M.L. has consulted for Medtronic, Boston Scientific and Abbott. S.A.S. has consulted for Boston Scientific, Neuropace and Zimmer Biomet. M.S.O. serves as medical advisor for the Parkinson’s Foundation; has received research grants from Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation; and has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge. All other authors declare no competing interests.
About this article
Cite this article
Visser-Vandewalle, V., Andrade, P., Mosley, P.E. et al. Deep brain stimulation for obsessive–compulsive disorder: a crisis of access. Nat Med (2022). https://doi.org/10.1038/s41591-022-01879-z